Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Stereotaxis ( (STXS) ) just unveiled an announcement.
On May 14, 2026, Stereotaxis held its Annual Meeting of Shareholders with approximately 65.34% of the 121,182,983 total voting power represented, satisfying quorum requirements. Shareholders voted on the election of three Class I directors to serve until the 2029 Annual Meeting, the ratification of the independent auditor for fiscal 2026, and an advisory executive compensation proposal.
All three board nominees – David Benfer, Arun Menawat, and Myriam Curet – were elected by plurality, securing solid majorities of votes cast despite substantial broker non-votes. Investors also strongly approved the ratification of Ernst & Young LLP as independent auditor and backed the company’s executive compensation program in the advisory say-on-pay vote, reinforcing board continuity and endorsing current governance and pay practices.
The most recent analyst rating on (STXS) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on Stereotaxis stock, see the STXS Stock Forecast page.
Spark’s Take on STXS Stock
According to Spark, TipRanks’ AI Analyst, STXS is a Neutral.
The score is held down primarily by weak financial performance (large losses and sustained cash burn) and bearish technical trend signals. These are partially offset by a more constructive earnings-call outlook, including reiterated >$40M FY2026 guidance and product/regulatory catalysts, but execution and funding risks remain meaningful.
To see Spark’s full report on STXS stock, click here.
More about Stereotaxis
Stereotaxis operates in the medical technology industry, focusing on advanced robotic systems for minimally invasive interventional procedures. The company’s products and services are primarily aimed at hospitals and physicians treating complex cardiac arrhythmias and other vascular conditions, with an emphasis on precision, safety, and improved patient outcomes.
Average Trading Volume: 420,404
Technical Sentiment Signal: Sell
Current Market Cap: $189.6M
See more data about STXS stock on TipRanks’ Stock Analysis page.